Clinical EffectsOne study looked at using docetaxel (the active ingredient of Docefrez) to treat advanced or metastatic breast cancer (cancer that has spread to other areas of the body) in people who had not adequately responded to certain other types of chemotherapy. In this study, people were given either docetaxel or a combination of mitomycin (Mitozytrex®) and vinblastine (Velban®). Compared to the combination treatment, docetaxel increased survival from 8.7 months to 11.4 months. It also delayed the progression of the cancer by almost two months.
Docetaxel was also studied for locally advanced or metastatic non-small cell lung cancer (NSCLC) that could not be treated with surgery and had not responded to previous "platinum-based" chemotherapy. Compared to supportive care (which is care to improve the quality of life but not to treat the cancer), docetaxel extended the survival time by almost two months and delayed the progression of the cancer by about five weeks.
In addition, docetaxel was studied for the treatment of hormone-refractory metastatic prostate cancer. In this study, people given docetaxel in combination with prednisone survived an average of 18.9 months, compared with 16.5 months in people who were given a different chemotherapy medication called mitoxantrone (Novantrone®) in combination with prednisone.
When and How to Receive ItSome general considerations to keep in mind during treatment with Docefrez include the following:
- This medication is given as a slow injection into a vein (an intravenous, or IV, infusion). It is usually given once every three weeks.
- The injections are normally administered by a healthcare provider in a healthcare setting, such as a hospital.
- It will take approximately one hour to receive your Docefrez dosage.
- For the medication to work properly, it must be used as prescribed.